From the *Department of Psychiatry, University of California, San Francisco, San Francisco, CA;
†Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC; and
‡Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX.
Received for publication June 22, 2018; accepted September 10, 2018.
Reprints: Katherine Scangos, MD, PhD, Department of Psychiatry, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94143 (e-mail: [email protected]).
Supported by MH40159 (R.D.W. and C.E.C.) and MH41803 (C.E.C.).
A.D.K. is a consultant for Ferring, Galderma, Jazz, Janssen, Takeda, Merck, Neurocrine, Otsuka, Pfizer, Lundbeck, Pernix, Idorsia, Adare, and Harmony Biosciences. The other authors report no conflicts of interest.